Cipher Pharmaceuticals Stock Current Valuation
| CPHRFDelisted Stock | USD 2.57 0.00 0.00% |
Valuation analysis of Cipher Pharmaceuticals helps investors to measure Cipher Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Cipher Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Cipher Pharmaceuticals is based on 3 months time horizon. Increasing Cipher Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cipher otc stock is determined by what a typical buyer is willing to pay for full or partial control of Cipher Pharmaceuticals. Since Cipher Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cipher OTC Stock. However, Cipher Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.57 | Real 2.44 | Hype 2.57 |
The real value of Cipher OTC Stock, also known as its intrinsic value, is the underlying worth of Cipher Pharmaceuticals OTC Stock, which is reflected in its stock price. It is based on Cipher Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cipher Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cipher Pharmaceuticals helps investors to forecast how Cipher otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cipher Pharmaceuticals more accurately as focusing exclusively on Cipher Pharmaceuticals' fundamentals will not take into account other important factors: Cipher Pharmaceuticals OTC Stock Current Valuation Analysis
Cipher Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Cipher Pharmaceuticals Current Valuation | 46.13 M |
Most of Cipher Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Cipher Pharmaceuticals has a Current Valuation of 46.13 M. This is 99.68% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United States stocks is 99.72% higher than that of the company.
Cipher Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Cipher Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.45 % | ||||
| Operating Margin | 0.57 % | ||||
| Current Valuation | 46.13 M | ||||
| Shares Outstanding | 25.12 M | ||||
| Shares Owned By Insiders | 44.12 % | ||||
| Number Of Shares Shorted | 11.43 K | ||||
| Price To Earning | 15.54 X | ||||
| Price To Book | 1.63 X | ||||
| Price To Sales | 3.28 X | ||||
| Revenue | 21.94 M | ||||
| Gross Profit | 18.26 M | ||||
| EBITDA | 11.85 M | ||||
| Net Income | 7.76 M | ||||
| Cash And Equivalents | 24.19 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 507 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 2.51 X | ||||
| Book Value Per Share | 1.77 X | ||||
| Cash Flow From Operations | 13.81 M | ||||
| Short Ratio | 0.97 X | ||||
| Earnings Per Share | 0.36 X | ||||
| Target Price | 5.59 | ||||
| Number Of Employees | 26 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 64.32 M | ||||
| Total Asset | 51.65 M | ||||
| Z Score | 75.6 | ||||
| Net Asset | 51.65 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Cipher OTC Stock
If you are still planning to invest in Cipher Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cipher Pharmaceuticals' history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |